Encorafenib/Binimetinib for the Treatment of BRAF-mutant Advanced, Unresectable, or Metastatic Melanoma: Design, Development, and Potential Place in Therapy

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s171693
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Development of Encorafenib for BRAF-mutated Advanced Melanoma

Current Opinion in Oncology
Cancer ResearchOncology
2018English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Benralizumab in the Treatment of Severe Asthma: Design, Development and Potential Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Comparative Efficacy of Combination Immunotherapy and Targeted Therapy in the Treatment of BRAF-mutant Advanced Melanoma: A Matching-Adjusted Indirect Comparison

Immunotherapy
OncologyAllergyImmunology
2019English

Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy

Therapeutic Advances in Medical Oncology
Oncology
2015English

Detection of Mutant BRAF Alleles in the Plasma of Patients With Metastatic Melanoma

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2007English

Cessation of Targeted Therapy After a Complete Response in BRAF-mutant Advanced Melanoma: A Case Series

British Journal of Cancer
Cancer ResearchOncology
2016English

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

PLoS ONE
Multidisciplinary
2015English

PCN87 Cost Effectiveness Evaluation of Vemurafenib, an Orphan Drug for Braf Mutant Metastatic Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy